JaLCDOI 10.18926/AMO/54514
フルテキストURL 70_4_327.pdf
著者 Watanabe, Mototsugu| Yamamoto, Hiromasa| Eikawa, Shingo| Shien, Kazuhiko| Shien, Tadahiko| Soh, Junichi| Hotta, Katsuyuki| Wada, Jun| Hinotsu, Shiro| Fujiwara, Toshiyoshi| Kiura, Katsuyuki| Doihara, Hiroyoshi| Miyoshi, Shinichiro| Udono, Heiichiro| Toyooka, Shinichi|
抄録 A study to evaluate the effect of metformin on the immune system was commenced in July 2014. Metformin is one of the most commonly prescribed drugs for type 2 diabetes, and previous studies have reported that metformin has an anti-tumor effect. The aim of this study is to evaluate the efficacy of metformin on the immune system in human cancer patients in vivo. The primary outcome parameter will be the rate change in the population of CD8+ T cells, which produce multiple cytokines.
キーワード metformin CD8+ T cells cancer immunology
Amo Type Clinical Study Protocols
発行日 2016-08
出版物タイトル Acta Medica Okayama
70巻
4号
出版者 Okayama University Medical School
開始ページ 327
終了ページ 330
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 27549683
Web of Sience KeyUT 000384748600018
タイトル(別表記) The 2014 Incentive Award of the Okayama Medical Association in Cancer Research (2014 Hayashibara Prize and Yamada Prize)
フルテキストURL 127_183.pdf
著者 榮川 伸吾|
備考 平成26年度岡山医学会賞紹介記事(The 2014 Okayama Medical Association Awards) 受賞対象論文 : Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H : Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A (2015) 112, 1809-1814.
出版物タイトル 岡山医学会雑誌
発行日 2015-12-01
127巻
3号
出版者 岡山医学会
出版者(別表記) Okayama Medical Association
開始ページ 183
終了ページ 186
ISSN 0030-1558
NCID AN00032489
資料タイプ 学術雑誌論文
関連URL isVersionOf https://doi.org/10.4044/joma.127.183
言語 Japanese
著作権者 Copyright (c) 2015 岡山医学会
論文のバージョン publisher
査読 有り
DOI 10.4044/joma.127.183
NAID 130005116818
Sort Key 3
Eprints Journal Name joma
参考文献 1)Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD : Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 330, 1304-1305. 2)Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, et al. : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369, 122-133.
タイトル(別表記) PD-1,CTLA-4
フルテキストURL 127_63.pdf
著者 榮川 伸吾|
備考 キーワード (Key word)
出版物タイトル 岡山医学会雑誌
発行日 2015-04-01
127巻
1号
出版者 岡山医学会
出版者(別表記) Okayama Medical Association
開始ページ 63
終了ページ 65
ISSN 0030-1558
NCID AN00032489
資料タイプ 学術雑誌論文
言語 Japanese
著作権者 Copyright (c) 2015 岡山医学会
論文のバージョン publisher
査読 有り
DOI 10.4044/joma.127.63
NAID 130005068337
Sort Key 14
Eprints Journal Name joma
参考文献 1) Wherry EJ : T cell exhaustion. Nat Immunol (2011) 12, 492-499. 2) Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, et al. : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369, 122-133. 3) Ishida Y, Agata Y, Shibahara K, Honjo T : Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J (1992) 11, 3887-3895. 4) Nishimura H, Nose M, Hiai H, Minato N, Honjo T : Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 11, 141-151. 5) Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T : Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 291, 319-322. 6) Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H : Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 169, 5538-5545. 7) Schreiner B, Mitsdoerffer M, Kieseier BC, Chen L, Hartung HP, Weller M, Wiendl H : Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation : relevance for the immune modulatory effect in multiple sclerosis. J Neuroimmunol (2004) 155, 172-182. 8) Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiu Y, Jussif JM, Carter LL, Wood CR, Chaudhary D : PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 574, 37-41. 9) Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, Golstein P : A new member of the immunoglobulin superfamily CTLA-4. Nature (1987) 328, 267-270. 10) Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL : CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol (2005) 25, 9543-9553.